Solid spruiking mate. I appreciate what you're saying, however,...

Solid spruiking mate. I appreciate what you're saying, however, the fundamentals and seized opportunities have always been first class.

What hasn't been first class is the speed of implementations and this is predominantly what has held Painchek back, along with lack of director buying, until this year of course.

The product sells itself and is clearly getting all sorts of love and acceptance around the globe. The implementation rate never really improved dramatically to align with increase of sales in a post pandemic world. For example the UK, sales contracts increased 100% last FY but the implementation rate was significantly lower. The past two quarterlies have highlighted they're addressing this issue by outsourcing etc and therefore, imo, it's one of the most important aspects of this month's report.

Daffas/mgt did a great job to keep this business afloat during the pandemic, mostly due to raising around $10m as the pandemic begun (a master stroke in hindsight that was highly unpopular at the time). They've just pulled off another master stroke in raising $3m into good hands, which will get them to FDA approval. This has definitely factored into the recent move in the share price. Of course, if FDA gives the green light, the stock will bounce significantly.

The question is whether they can crack into that 2m bed market with a high implementation rate because unless they complete a funding partnership with Phillips, for example, the current implementation rate will see them needing to raise some more cash next year. This, in turn, could slow down sp growth.

Still a strong bull here. Hard to see the 'end of the road' for Painchek not resulting in a sp SIGNIFICANTLY higher then current sp. Whether that's 5+ years of organic growth, competing takeover bids post fda approval or, as mentioned, a strategic financial partnership with the likes of Phillips. Cheers